STAAR Surgical Attracts Top Industry Executives Arthur Butcher and Wei Jiang to its Board of Directors
Lake Forest, Calif. - STAAR Surgical Company (NASDAQ: STAA), a renowned leader in the development, manufacturing, and marketing of the innovative EVO family of Implantable Collamer Lenses (ICL) for the correction of myopia, astigmatism, and presbyopia, proudly announces the appointment of two distinguished industry leaders, Arthur Butcher and Wei Jiang, to its esteemed Board of Directors.
Arthur Butcher, currently serving as the Executive Vice President and Group President of MedSurg and Asia Pacific for Boston Scientific, brings with him a wealth of knowledge, experience, and strategic insights into the global healthcare sphere. With his proven track record of driving growth and transformation within the medical device industry, Butcher’s addition to STAAR Surgical’s Board is expected to be a significant asset in expanding the company’s global footprint.
Wei Jiang, a highly acclaimed retired Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC, joins the esteemed STAAR Surgical Board with a remarkable legacy of corporate leadership and extensive experience in international markets. His unparalleled expertise in navigating complex regulatory environments and fostering strong relationships in the Asia Pacific region will be invaluable as STAAR Surgical aims to enhance its market presence and cultivate partnerships in this rapidly expanding market.
The inclusion of these distinguished individuals on STAAR Surgical’s Board is a testament to the company’s commitment to delivering cutting-edge ophthalmic solutions and furthering its position as a global leader in the field. With their profound industry expertise and strategic vision, Butcher and Jiang will undoubtedly play a vital role in shaping STAAR’s future and elevating its success to new heights.
STAAR Surgical continues to revolutionize the ophthalmic industry with its EVO family of Implantable Collamer Lenses, a revolutionary technology that has garnered immense recognition and success. This vision correction solution provides patients with improved visual acuity and quality of life, alleviating the burden of visual impairments associated with myopia, astigmatism, and presbyopia.
Furthermore, the company’s relentless commitment to innovation and research has led to breakthrough advancements, propelling STAAR Surgical to achieve an outstanding growth rate of 20.62% in 2024. This exceptional performance is a testament to the company’s unwavering dedication to providing patients worldwide with the best possible ophthalmic solutions.
With Butcher and Jiang joining STAAR Surgical’s esteemed Board of Directors, the company is poised to leverage their extensive industry expertise and strategic vision to capitalize on new opportunities and accelerate its growth trajectory. As key decision-makers, they will collaborate closely with STAAR Surgical’s executive team to chart a path for global expansion, penetrate emerging markets, and drive the adoption of its groundbreaking EVO ICL technology.
In this exciting new chapter, Arthur Butcher and Wei Jiang’s inclusion in STAAR Surgical’s Board of Directors signals a promising future ahead. Their wealth of experience and remarkable achievements in the medical device and pharmaceutical sectors will undoubtedly propel STAAR Surgical to new horizons, enabling countless individuals worldwide to benefit from cutting-edge, life-changing ophthalmic innovations.
Comments